MergerApr 29, 2026, 08:37 AM
KALV acquired by Chiesi for $27.00/share, total $1.9B
AI Summary
Chiesi Group announced a definitive agreement to acquire KalVista Pharmaceuticals, Inc. for $27.00 per share in cash, valuing the company at approximately $1.9 billion. This represents a 36% premium to KalVista's recent 30-day average share price. The acquisition, unanimously approved by both boards, is expected to close in Q3 2026 and will significantly expand Chiesi's rare disease portfolio with EKTERLY® (sebetralstat), an approved oral treatment for hereditary angioedema.
Key Highlights
- Chiesi Group to acquire KalVista Pharmaceuticals for $27.00 per share in cash.
- Total equity consideration for the transaction is approximately $1.9 billion.
- The offer price represents a 36% premium to KalVista's 30-day volume-weighted average share price as of April 28, 2026.
- The transaction was unanimously approved by both Chiesi's and KalVista's Boards of Directors.
- The acquisition is expected to close in Q3 2026, subject to customary closing conditions.
- Chiesi will assume responsibility for EKTERLY® (sebetralstat), an oral, on-demand treatment for hereditary angioedema (HAE).
- Sebetralstat generated $49M in sales in 2025 following its US launch.
- The acquisition is expected to contribute to Chiesi's 2030 strategic revenue target of €6bn.